Posted by Michael Wonder on 03 Apr 2023
Sandoz receives approval by European Commission for Hyrimoz (adalimumab) high-concentration formulation
3 April 2023 - Biosimilar Hyrimoz (adalimumab) citrate free high concentration formulation is now approved in the EU for use in all indications of reference medicine Humira.
Sandoz today announced that the European Commission granted marketing authorization in the European Union for a citrate-free high concentration formulation (100 mg/mL) of its biosimilar Hyrimoz (adalimumab).
The approval includes all indications covered by the reference medicine: rheumatic diseases, Crohn's disease, ulcerative colitis, plaque psoriasis, uveitis and hidradenitis suppurativa.
